Claudin

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Retrieved on: 
Tuesday, May 23, 2023
Pancreatic cancer, Prevalence, ODD, New Drug Application, NDA, Cancer, Hubli railway division, Cell, Claudin, Patient, Cell polarity, Hematology, National Medical Products Administration, ADC, Diagnosis, Rare, FDA, Stomach, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMPA, Food, Cell adhesion, Pharmaceutical industry

To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.

Key Points: 
  • To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.
  • Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions.
  • The Claudin 18.2 isoform is overexpressed in various primary malignant tumors including gastric, esophageal and pancreatic cancers.
  • Moving forward, Antengene will work closely with regulators and clinical investigators to advance the CLINCH trial and fully assess ATG-022's therapeutic potential for solid tumors."

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

Retrieved on: 
Thursday, April 13, 2023
Partnership, Hereditary diffuse gastric cancer, INSERM, Cancer, T cell, Do Meu Jeito, Antibody, Doctor of Philosophy, Lung, Fibrosis, Novo Holdings A/S, MD, Patient, Biology, ADC, Growth, R, Phase, Claudin, Therapy, Pharmaceutical industry, CLDN1

The financing was led by Jeito together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.

Key Points: 
  • The financing was led by Jeito together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
  • Funds will also be used to develop the Company’s platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies.
  • Jeito became a key investor in Alentis as part of a $67 million Series B financing in June 2021.
  • Dr. Roberto Iacone, CEO at Alentis Therapeutics, said: “We are absolutely delighted with this support from our investors.

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

Retrieved on: 
Tuesday, February 28, 2023
ODD, Speech, Rare, Diagnosis, Policy, Colon, Claudin, Stomach, Pancreatic cancer, Center for Drug Evaluation and Research, Permeability, MG, Research, Social responsibility, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Autoantibody, Liver, Myasthenia gravis, CDE, US Food Sovereignty Alliance, GMG, Neuromuscular junction, United, ADC, Breast, Food, Cancer, US, Pharmaceutical industry

YANTAI, China, Feb. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023's message of continuing to increase visibility and generate change for the millions of people globally living with a rare disease, their families and carers.

Key Points: 
  • YANTAI, China, Feb. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023's message of continuing to increase visibility and generate change for the millions of people globally living with a rare disease, their families and carers.
  • RemeGen takes immense pride in observing this special day and will be there to help and support all those living with rare diseases."
  • Rare Disease Day is a global movement focused on rare diseases that pushes for equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.
  • Orphan drugs, also known as rare disease drugs, are used for the prevention, treatment, and diagnosis of rare diseases.

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

Retrieved on: 
Wednesday, April 20, 2022
IND, CDC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Stomach, Pancreatic cancer, Food, Claudin, Review, Apoptosis, MMAE, ADCC, Safety, FDA, ADC, Zolbetuximab, Pharmaceutical industry, Vaccine

CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.

Key Points: 
  • CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
  • Among all the Claudin 18.2-targeted drugs, CMG901 is the first and only one which received this FDA designation so far.
  • This designation was granted based on the phase 1 studies that assessed the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of CMG901.
  • Preclinical studies suggest that CMG901 can effectively kill gastric cancer cells with much stronger antitumor potency than zolbetuximab analog or the unconjugated antibody of CMG901.